Although anti-HER2 targeted therapy has been mainly developed in breast and gastric cancer, recent comprehensive molecular profiling has demonstrated an incidence of ErbB family mutations, amplifications and over-expression in up to 20–30% of BC patients [31], with particularly high rates of HER2 alterations in micropapillary bladder tumors [32]. Here, ERBB2 is linked to gastric cancer.